Clinical Trial Update: Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer

View source ↗

Summary

A clinical trial update describes using vinorelbine and ifosfamide as a third-line therapy for refractory small cell lung cancer; the trial status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• IFOSFAMIDE (IFOSFAMIDE)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Small Cell Lung Cancer | Status: UNKNOWN